Lyra Therapeutics Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced a $29.5 million Series B equity financing.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2018-09-26 12:49:252018-09-27 15:01:50Lyra Therapeutics Announces $29.5 Million Series B Financing to Advance Innovative Therapeutics for Ear, Nose and Throat Diseases
